Increased adipose tissue is associated with improved overall survival, independent of skeletal muscle mass in non-small cell lung cancer.

Abstract

The prognostic significance of non-cancer-related prognostic factors, such as body composition, has gained extensive attention in oncological research. Compared with sarcopenia, the prognostic significance of adipose tissue for overall survival in non-small cell lung cancer remains unclear. We investigated the prognostic value of skeletal muscle and adipose tissue in patients with non-small cell lung cancer. This retrospective study included 4434 patients diagnosed with non-small cell lung cancer between January 2014 and December 2016. Cross-sectional areas of skeletal muscle and subcutaneous fat were measured, and the pericardial fat volume was automatically calculated. The skeletal muscle index and subcutaneous fat index were calculated as skeletal muscle area and subcutaneous fat area divided by height squared, respectively, and the pericardial fat index was calculated as pericardial fat volume divided by body surface area. The association between body composition and outcomes was evaluated using Cox proportional hazards model. A total of 750 patients (501 males [66.8%] and 249 females [33.2%]; mean age, 60.9±9.8years) were included. Sarcopenia (60.8% vs. 52.7%; P<0.001), decreased subcutaneous fat index (51.4% vs. 25.2%; P<0.001) and decreased pericardial fat index (55.4% vs. 16.5%; P<0.001) were more commonly found in the deceased group than survived group. In multivariable Cox regression analysis, after adjusting for clinical variables, increased subcutaneous fat index (hazard ratio [HR]=0.56, 95% confidence interval [CI]: 0.47-0.66, P<0.001) and increased pericardial fat index (HR=0.47, 95% CI: 0.40-0.56, P<0.001) were associated with longer overall survival. For stage I-III patients, increased subcutaneous fat index (HR=0.62, 95% CI: 0.48-0.76, P<0.001) and increased pericardial fat index (HR=0.43, 95% CI: 0.34-0.54, P<0.001) were associated with better 5-year overall survival rate. Similar results were recorded in stage IV patients. For patients with surgery, the prognostic value of increased subcutaneous fat index (HR=0.60, 95% CI: 0.44-0.80, P=0.001) and increased pericardial fat index (HR=0.51, 95% CI: 0.38-0.68, P<0.001) remained and predicted favourable overall survival. Non-surgical patients showed similar results as surgical patients. No association was noted between sarcopenia and overall survival (P>0.05). Increased subcutaneous fat index and pericardial fat index were associated with a higher 5-year overall survival rate, independent of sarcopenia, in non-small cell lung cancer and may indicate a reduced risk of non-cancer-related death.